ArticleInternational journal of clinical oncology2020

Comparable efficacy and safety between second-line and later-line nivolumab therapy for metastatic renal cell carcinoma.

Hiroki Ishihara et al.PubMed ↗Publisher ↗

No numbers read from the abstract.